1. Baxalta Gmbh (52 from 151 patents)

2. Baxter International Inc. (44 from 2,468 patents)

3. Baxter Healthcare Sa (43 from 1,138 patents)

4. Immuno Aktiengesellschaft (16 from 83 patents)

5. Baxter Aktiengesellschaft (14 from 67 patents)

6. Takeda Pharmaceutical Company Limited (9 from 1,172 patents)

7. Nektar Therapeutics (4 from 415 patents)

8. Baxter Innovations Gmbh (4 from 12 patents)

9. Stichting Sanquin Bloedvoorziening (3 from 27 patents)

10. Lipoxen Technologies Incorporated (2 from 57 patents)

11. Baxter Healthcare Inc. (1 from 24 patents)

12. Baxler Innovations Gmbh (1 from 1 patent)

13. Immuno Aktiengesllschaft (1 from 1 patent)

1. 12178861 - Stabilized liquid and lyophilized ADAMTS13 formulations

2. 11564992 - Nucleophilic catalysts for oxime linkage

3. 11564979 - Stabilized liquid and lyophilized ADAMTS13 formulations

4. 11197916 - Lyophilized recombinant VWF formulations

5. 11191813 - Lyophilized recombinant VWF formulations

6. 11191837 - Recombinant VWF formulations

7. 11160850 - Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

8. 11040109 - Blood coagulation protein conjugates

9. 11020458 - Factor VIII polymer conjugates

10. 10900979 - Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)

11. 10772968 - Glycopolysialylation of non-blood coagulation proteins

12. 10758599 - Stabilized liquid and lyophilized ADAMTS13 formulations

13. 10576160 - Nucleophilic catalysts for oxime linkage

14. 10414793 - Nucleophilic catalysts for oxime linkage

15. 10350301 - Blood coagulation protein conjugates